BioWorld MedTech

Aug. 24, 2016

View Archived Issues

Iglarlixi delay puts more eyes on PRVs as business tool

Clinical utility still a major hurdle for potential coverage of novel diagnostics

Mylan tries to deflect public shaming on social media over the cost of Epipen

Daily M&A

Appointments and advancements

Other news to note

Product briefs

MDD's Oncology Extra

Lengthy MDUFA talks yield tentative agreement between FDA, industry

Three entities representing the medical device and imaging communities are heralding a tentative agreement with the FDA for the fourth reauthorization of a medical device user fee program. Read More

FDA a good sport, clears first concussion-specific computerized tests

Today's news in brief

BioWorld

BioWorld briefs for April 8, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for April 8, 2025.

Pfizer’s PF-07853578 is candidate to treat MASH

BioWorld Science

The I148M mutation in the PNPLA3 gene, which encodes patatin-like phospholipase domain-containing protein 3, is known to confer risk of fatty liver, cirrhosis and...

Caution tape displaying US flag, tariffs

Biopharma exempt from US reciprocal tariffs, but not untouched

BioWorld

At first glance, it appears that biopharmaceuticals dodged the latest U.S. tariff bullet; med-tech, not so much. According to the executive order President Donald...

PFA non-inferior, even superior, to cryoablation for paroxysmal AF

BioWorld MedTech

Pulsed field ablation using Boston Scientific Corp.’s Farapulse system was non-inferior and even superior, slightly, to Medtronic plc’s Artic Front Advance...